Abstract
Background Vitiligo is an acquired autoimmune pigmentary disorder characterized by ivory white patches. Zinc is proposed to have an immune modulatory, antioxidant and antiapoptotic properties in vitiligo patients. The aim of this study is to evaluate serum zinc in vitiligo patients.
Patients and methods This is case–control study conducted from December 2019 to May 2020. The study included 50 patient with vitiligo and 50 age- and sex-matched controls. A 2 ml venous blood sample was taken from patients and controls by zinc-free syringe and was measured by atomic absorption spectrophotometry.
Results The mean serum zinc level was 73.14±19.32 in patients group and 85.36±14.14 in controls group (p-value=0.005). It also was 77.65±22.07 and 82.84±14.32 in male patients and controls, respectively. In female patients, it was 70.82±17.65and in female controls was 82.88±13.79(p-value=0.02). Regarding the residence, the mean serum zinc level in patients group was 70.13±21.4 in urban and 76.39±17.73 in rural area. In controls group, mean serum zinc was 83.25±14.12 and 89.11±13.77 in urban and rural area, respectively (p-value=0.003). According to the clinical patterns of vitiligo, the mean serum zinc observed was 75.32±19.64 in vitiligo vulgaris, 70.45±21.23 in acrofacial vitiligo and 68.7±17.61 in segmental vitiligo (p-value=0.68).
Conclusion Serum zinc level was significantly low in patients with vitiligo but not associated with the type of vitiligo or family history of autoimmune diseases. It was even lower when vitiligo is associated with nail changes than vitiligo without any nail abnormalities.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
All the authors received no funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the ethical committee at the Dermatology department, College of Medicine, Tikrit University
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The manuscript was made available on google drive link.
